Cell line · CVCL_0359
Papers68
1 to 20 of 68
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Investigation of the significance and role of androgen receptor expression in basal/squamous type urothelial carcinoma cell line J82 cells. | BMC Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ZW4864-mediated inhibition of the β-catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| O-GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TIMP1 Derived from Mesenchymal Stem Cells Promotes Bladder Cancer Progression by Regulating the Formation of VDIMs through the RAP1 Pathway. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combining 5-ALA-PDT with berbamine as an in vitro multimodal therapy approach against bladder cancer cells. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| m5C-Modified tRF3b-CysGCA-23 Suppresses Bladder Cancer Malignancy by Repressing H3K18 Lactylation via Stabilizing RBM4. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic strategies for MMAE-resistant bladder cancer through DPP4 inhibition. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| piR-43452 suppresses bladder cancer progression and enhances gemcitabine sensitivity via GTSF1/PIWIL4-mediated LRP1 mRNA destabilization. | Transl Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Histone deacetylase HDAC7 restricts CD8 + T cell tumor infiltration and limits immunotherapy sensitivity in bladder cancer: reversal by pinocembrin. | J Exp Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Stem Cell-Related Gene CALR as a Novel Prognostic Factor for Bladder Cancer: Implications for Immunotherapy. | Hum Mutat | 2025 | Its Methods give the RRID and name the line | PubMed | |
| HLA-E and NKG2A Mediate Resistance to BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse. | Int J Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| IMP2 drives chemoresistance by repressing cisplatin-induced apoptosis and ferroptosis via activation of IPO4 and SLC7A11 under hypoxia in bladder cancer. | Cancer Cell Int | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Proteomic analysis of the urothelial cancer landscape. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Dual role of GRHL3 in bladder carcinogenesis depending on histological subtypes. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Comprehensive identification of onco-exaptation events in bladder cancer cell lines revealed L1PA2-SYT1 as a prognosis-relevant event. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0359/papers